Global Chronic Migraine Treatment Market: Introduction
Migraine is a painful episodic disorder that sometimes develops into a chronic form. It is one of the most prevalent neurological conditions in clinical practice. Chronic migraine (CM) is the natural development of migraine in its chronic form and has a headache frequency of 15 days per month with similar characteristics to migraine assaults. Many patients with chronic migraine also have overuse of medication, described as at least 10 days per month using a compound analgesic, opioid, triptan, or ergot derivative.
Global Chronic Migraine Treatment Market: Competitive Landscape
Founded in 1996, Novartis AG is among the top global pharmaceutical companies operating across all the geographies in almost all the specialties. It was established through the merger of Ciba-Geigy and Sandoz in 1996. It acquired Alcon, Inc. and expanded its base in eye care market. Novartis operates in patented pharmaceutical products, generic pharmaceuticals & biosimilars, and surgical and vision care segments. It offers many OTC as well as generic drugs for acute attack treatment of migraine. The company is investing into specialty prophylactic treatment drugs through its recent acquisitions and strategic collaborations.
Need an Overview of the Report on Chronic Migraine Treatment Market? Ask for the Brochure here
Incorporated in 1849, Pfizer Inc. is one of the leading biopharmaceutical companies. The company manages its commercial operations through two segments: Global Innovative Products and Global Essential Health. The global innovative products segment includes pharmaceutical sub-segment that focuses on novel pharmaceutical products, vaccines, oncology products, and consumer healthcare. The global essential health segment includes branded generics, generics, biosimilar, and infusion systems. Pfizer has expanded its neurosciences product portfolio through indigenous product developments and acquisitions across the market. The company offers OTC and prescription drugs for migraine treatment in the form of tablets as well as other forms.
Other key players operating in the global chronic migraine treatment market include AstraZeneca Plc., Allergan Plc., GlaxoSmithKline Plc., Eli Lilly & Company, Merck & Co., Inc., Janssen Pharmaceutical Company (Johnson & Johnson), Endo Pharmaceutical Inc., Zosano Pharma Corporation, Alder BioPharmaceutical, Inc., Eisai Co., Ltd., and Avanir Pharmaceuticals, Inc.
Global Chronic Migraine Treatment Market: Dynamics
High Prevalence of Migraine and Increasing Transition from Episodic to Chronic Migraine to Drive the Market
According to a report by the World Health Organization (WHO), in 2013, migraine was the 6th most common cause for a year lost due to disability across the globe. According to a study, titled “Lifting the Burden”, conducted by World Health Organization and other prominent institutes in 2011, the prevalence of migraine across the globe was around 11.0%. Other independent studies suggest this prevalence to be around 14.7%. Prevalence of migraine among females is supposed to be 2 to 3 times more than in men. According to The Migraine Trust of the U.K., around 2% of the world population is estimated to be affected by chronic migraine. Furthermore, it is estimated that around 2 to 3% of episodic migraine patients transitioned to chronic migraine patients. Migraine attacks are triggered by various factors such as environmental change, hormonal imbalance, and dietary change. Rise in incidences of these triggering factors is projected to increase the number of episodic migraine patients, which in turn, is likely to increase chronic migraine patients’ population.
Stuck in a Neck-to-Neck Competition with other Brands? Request a Custom Report on “Chronic Migraine Treatment Market” here
Ongoing Investment in Alternative Therapies to Restrain the Market
Various complementary alternative therapies are being practiced for chronic migraine treatment such as manual therapy, chiropractic, homeopathy, and Ayurveda. It is estimated that emerging and under-developed markets prominently use complementary alternative therapies for migraine treatment. According to a study conducted by physicians and scientists of Harvard Medical School of Boston, Massachusetts, U.S. in 2011, around 4.5% of adults in the U.S. relied on complementary alternative therapies to relieve migraine. Key industry players and research institutes are investing into development of new portable neuro-stimulating devices to offer abortive as well prophylactic treatment of migraine. Recent FDA approvals for such devices are projected to attract new players in this market. A few examples of such devices include sTMS mini by eNeuro, and Cefaly by Roxon.
Global Chronic Migraine Treatment Market: Segmentation
The global chronic migraine treatment market can be segmented based on:
- Route of Administration
- Distribution Channel
Global Chronic Migraine Treatment Market, by Treatment
In terms of treatment, the global chronic migraine treatment market can be divided into:
- Abortive Treatment
- Ergot Alkaloids
- Prophylactic Treatment
- Botulinum Toxin
Global Chronic Migraine Treatment Market, by Route of Administration
Based on route of administration, the global chronic migraine treatment market can be classified into:
- Others (Nasal Spray, Transdermal Patch, suppositories)
Global Chronic Migraine Treatment Market, by Distribution Channel
In terms of distribution channel, the global chronic migraine treatment market can be segregated into:
- Hospitals Pharmacies
- Retail Pharmacies
- Others (Online Pharmacies, Drug Stores)
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.